Detection of Resistance Mutation to Lamivudine in HIV-1 Infected Patients

Lamivudine 복용 HIV-1 감염자에게서 내성 돌연변이 검색

  • Cho, Young-Keol (Department of Microbiology, University of Ulsan College of Medicine) ;
  • Sung, Heung-Sup (Department of Microbiology, University of Ulsan College of Medicine) ;
  • Lee, Hee-Jung (Department of Microbiology, University of Ulsan College of Medicine) ;
  • Kim, Yoo-Kyum (Department of Microbiology, University of Ulsan College of Medicine) ;
  • Chi, Hyun-Sook (Department of Clinical Pathology, University of Ulsan College of Medicine) ;
  • Cho, Goon-Jae (Department of Internal Medicine, Pusan National University Hospital) ;
  • Kang, Moon-Won (Department of Internal Medicine, Catholic University Medical College)
  • 조영걸 (울산대학교 의과대학 미생물학교실) ;
  • 성흥섭 (울산대학교 의과대학 미생물학교실) ;
  • 이희정 (울산대학교 의과대학 미생물학교실) ;
  • 김유겸 (울산대학교 의과대학 미생물학교실) ;
  • 지현숙 (울산대학교 의과대학 임상병리학교실) ;
  • 조군제 (부산대학교 의과대학 미생물학교실) ;
  • 강문원 (가톨릭대학교 의과대학 내과학교실)
  • Published : 2000.04.30

Abstract

To investigate resistance to lamivudine (3TC), we examined the incidence of M184V in 20 HIV-1 patients treated with 3TC for $13.1{\pm}9$ months. Fourteen of 20 patients had been exposed to zidovudine (ZDV) or didanosine (ddI) prior to 3TC therapy. Nested PCR targeting to reverse transcriptase (RT) and direct sequencing were performed for peripheral blood mononuclear cells sampled serially. There were resistance mutations to ZDV in at least 9 patients at baseline, although there was no resistance mutation to 3TC. We could detect M184V in 6 (30%) out of 20 patients. The incidence of M184V increased as the duration of therapy prolongs (13% in samples <12 months; 47% in samples ${\ge}12$ months). The frequency of mutation M184V was higher in patients with previous mutation to ZDV than in patients with wild type. Resistance mutation was not detected in 7 patients. This study shows that resistance to 3TC tends to develop rapidly in patients with baseline mutations or two drugs combination therapy than in those treated simultaneously with triple drugs. This report is the first on resistance to 3TC in Korean AIDS patients.

Keywords

References

  1. 대한바이러스학회지 v.29 인면역결핍바이러스 pol 유전자 염기서열 결정에 의한 지도부딘 (ZDV) 내성 돌연변이의 탐지 조영걸;이희정;성홍섭;김유겸;김영붕;이용진;김미정;김대곤;원영호;조군제
  2. 대한바이러스학회지 v.26 인면역결핍 바이러스 감염자에서 ICD-p24 항원 탐지가 CD4+ T 세포수 및 예후에 미치는 영향 조영걸;이희정
  3. 대한미생물학회지 v.32 HIV-1 C2/V3 region 염기서열 분석 및 이의 임상적 의의: 고려홍삼 복용시 HIV 유전자에 미치는 영향 조영걸;이희정;김영봉;오원일;김유겸
  4. AIDS v.12 Variations in HIV-1 pol gene associated with reduced sensitvity to antiretroviral drugs in treatment-naive patients Birk, M.;Sonnerborg, A.
  5. Ann Intern Med v.122 Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy D'Aquilla R.T.;Johnson, V.A.;Welles, S.I.(et al.)
  6. J Infect Dis v.179 Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologu outcome Deeks, S.G.;Hellmann, N.S.;Grant, R.M.;Parkin, N.T.;Petropoulos, C.J.;Becker, M.;Symonds, W.;Chesney, M.;Volberding, P.A.
  7. AIDS v.13 Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs de Jong, J.J.;Goudsmit, J.;Lukashov, V.V.;Hillebrand, M.E.;Baan, E.;Huismans, R.;Danner, S.A.;Ten Veen, J.H.;de Wolf, F.;Jurriaans, S.
  8. Nature Medicine v.5 Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy Finzi, D.;Blankson, J.;Siliciano, J.D.(et al.)
  9. Antimicrob Agents Chemother v.37 The same mutation that encodes low level human immuno-deficiency virus type-1 resistance to 2'.3'-dideoxyinosine and 2'.3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2'-2'-dideoxy-3'-thiacytidine Gao, Q.;Gu, Z.X.;Parniak, M.A.(et al.)
  10. Antimicrob Agents Chemother v.44 A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypec lamivudine resistance in the absence of mutation 184V Hertogs, K.;Bloor, S.;de Vroey, V.(et al.)
  11. JAMA v.279 Antiretroviral drug resistance testing in adults with HIV infection Hirsch, M.S.;Conway, B.;D'Aquila, R.T.;Johnson, V.A.;Brun-Vezinet, F.;Clotet, B.;Demeter, L.M.;Hammer, S.M.;Jacobsen, D.M.;Kuritzkes, D.R.;Loveday, C.;Mellors, J.W.;Vella, S.;Richman, D.D.
  12. J Infect Dis v.177 Altered drug sensitivity fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance Maeda, Y.;Venzon, D.J.;Mitsuya, H.
  13. AIDS v.13 Introduction of HIV drug-resistance testing in clinical practice Rodriguez-Rosado, R.;Briones. C.;Soriano, V.
  14. AIDS v.11 Increase in the frequency of mutation at coden 215 associated with zidovudine resistance in HIV-1 infected anti-viral-naive patients from 1989 to 1996 Rubio, A.;Leal, M.;Pineda, J.A.(et al.)
  15. J Infect Dis v.171 Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine(3TC) Schuurman, R.;Nijhuis, M.;Van Leeuwen, R.;Schipper, P.;de Jong, D.;Danner, S.A.;Mulder, J.;Loveday, C.;Christopherson, C.;Kwok, S.;Sninsky, J.;Boucher, C.A.B.
  16. J Infect Dis v.169 Apparent selection against transmission of zidovudine-resistant human immunodeficiency virus 1 variants Wahlberg, J.;Fiore, J.;Angarano, G.;Uhlen, M.;Albert, J.